That philosophy extends to how we discuss their application
This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)
On the other hand, treatment with L-ca 200 mg/kg increased the expression levels of catalase, GPx, and SOD compared to the MSG group and reversed its adverse effects to induce renal oxidative stress better than 100 mg/kg
[21] [22] The benefits of probiotics for weight management remain an area of ongoing research, with no definitive conclusions established
These are early signals, but ones that deserve careful attention and have clinical implications for how combination therapy of metformin and GLP-RA is approached in routine practice
